- Home
- CNTX vs INKT Comparison
CNTX vs INKT Comparison
Compare CNTX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- INKT
- Stock Information
- Founded
- CNTX 2015
- INKT 2017
- Country
- CNTX United States
- INKT United States
- Employees
- CNTX N/A
- INKT N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- CNTX Health Care
- INKT Health Care
- Exchange
- CNTX Nasdaq
- INKT Nasdaq
- Market Cap
- CNTX 75.6M
- INKT 69.2M
- IPO Year
- CNTX 2021
- INKT 2021
- Fundamental
- Price
- CNTX $1.26
- INKT $14.80
- Analyst Decision
- CNTX Strong Buy
- INKT Buy
- Analyst Count
- CNTX 7
- INKT 3
- Target Price
- CNTX $5.20
- INKT $37.50
- AVG Volume (30 Days)
- CNTX 500.2K
- INKT 29.8K
- Earning Date
- CNTX 11-10-2025
- INKT 11-13-2025
- Dividend Yield
- CNTX N/A
- INKT N/A
- EPS Growth
- CNTX N/A
- INKT N/A
- EPS
- CNTX N/A
- INKT N/A
- Revenue
- CNTX N/A
- INKT N/A
- Revenue This Year
- CNTX N/A
- INKT N/A
- Revenue Next Year
- CNTX N/A
- INKT N/A
- P/E Ratio
- CNTX N/A
- INKT N/A
- Revenue Growth
- CNTX N/A
- INKT N/A
- 52 Week Low
- CNTX $0.49
- INKT $4.56
- 52 Week High
- CNTX $2.46
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- CNTX 56.22
- INKT 52.44
- Support Level
- CNTX $1.19
- INKT $14.00
- Resistance Level
- CNTX $1.50
- INKT $15.35
- Average True Range (ATR)
- CNTX 0.15
- INKT 0.77
- MACD
- CNTX -0.02
- INKT 0.03
- Stochastic Oscillator
- CNTX 39.78
- INKT 70.74
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.